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Only a few years ago, alamandine was found to be a member of the protective arm
of the renin-angiotensin system. It turned out to be an endogenous ligand of the G
protein-coupled receptor MrgD. So far, MrgD had predominantly been studied in a
neuronal context. The expression of the receptor in non-neuronal tissue showed hitherto
unknown effects mediated by MrgD, most strikingly alamandine-induced vasodilation.
Alamandine being a part of the non-classical renin-angiotensin system, a protective role
of receptor activation seemed natural. This review summarizes the different effects of
MrgD activation by alamandine in vasculature, in the central nervous system, and in
organs as kidney and heart. Alamandine and MrgD are promising novel drug targets
to protect the kidney and heart through anti-hypertensive actions.
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INTRODUCTION
When it comes to discussing G protein-coupled receptors (GPCRs) involvement in the
development of hypertension, the first molecule that comes into everyone’s mind is usually
the angiotensin II receptor. The combination of the search terms “angiotensin receptor” and
“hypertension” presents more than 7,000 publications on Pubmed. Many of those publications
discuss the angiotensin II receptor subtype 1 (AT1R) as the “bad guy” promoting the development
of hypertension, inflammation, remodeling, and more. AT1R inhibition reduces blood pressure
and has anti-inflammatory and anti-proliferative effects. An increasing number of publications
emphasize the role of the angiotensin II receptor subtype 2 (AT2R) in the so-called protective
arm of the renin-angiotensin system (RAS). Following the development of hypertension research,
one will soon come across another receptor belonging to the protective arm of the RAS: the Mas
receptor. The search terms “Mas receptor” and “hypertension” still offer about 200 publications in
Pubmed. The Mas receptor can be activated by its ligand angiotensin (1-7) [Ang (1-7)]. Derived
from angiotensin II (Ang II) by Ang II-converting enzyme 2 (ACE2), it shows vasodilating
(thus protective) properties. Ang (1-7) can be decarboxylated to a peptide called alamandine.
Interestingly, alamandine was found to be an endogenous ligand for a GPCR related to Mas, the
Mas-related G protein-coupled receptor member D (MrgD), also known as TGR7 (1) or hGPCR45
(2). The structural resemblance of the ligands Ang (1-7) and alamandine as well as of the receptors
Mas andMrgD (3) suggests a possible role of MrgD in blood pressure regulation and hypertension,
respectively (Figure 1). Very surprisingly, the search term “MrgD” provides only 42 publications in
total on Pubmed. This can be explained by the fact that the investigation of the MrgD receptor in
non-neuronal tissue started only a few years ago.
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FIGURE 1 | Classical (black) vs. protective arm (green) of the renin-angiotensin system.
WHAT IS KNOWN ABOUT THE MRGD
RECEPTOR?
The responsible gene Mrgprd is found in rodents as well as
in humans (4), the coding sequence is located within a single
exon (5). First publications described the receptor expression as
constrained to a subset of pain-sensitive small-diameter neurons
(1, 4–6). The MrgD receptor was associated with a role in the
modulation of neuropathic pain (4, 5) and the perception of
itching (7). Coexpression withMrgE, another member of theMrg
family, was found in macaque peripheral nociceptive neurons
(8); both subtypes were shown to form heteromeres in HEK cells
(9). Expression of several Mrg receptor subtypes was increased in
mouse inflamed intestinal tissue (10, 11).
In a cardiovascular context, expression was detected in
arterial smooth muscle cells, endothelial nitric oxide synthase
(eNOS)-positive endothelial cells, and in atherosclerotic
plaques (12). Oliveira et al. localized the receptor in blood
vessels, cardiomyocytes (mainly in the membrane, perinuclear,
and nuclear region), and the cardiovascular center of the
mouse brain. They also studied MrgD-deficient mice and
found left ventricular remodeling and a pronounced dilated
cardiomyopathy, decreasing the systolic function of the mice
(13). If treated with angiotensin II, hearts of spontaneously
hypertensive rats (SHR) and cardiomyocytes showed an
increased expression of MrgD. TheMrgD ligand alamandine was
able to attenuate hypertension and alleviate cardiac hypertrophy
in this model (14).
G PROTEIN COUPLING
The MrgD receptor is G protein-coupled. Most studies were
performed in heterologous expression systems, interestingly
suggesting a possible coupling to different heterotrimeric G
protein subtypes (Table 1). Shinohara et al. were the first ones
to show that ß-alanine, a neurotransmitter and a ligand of the
MrgD receptor, initiates calcium influx into MrgD-expressing
Chinese hamster ovary (CHO) cells (indicating Gq protein
coupling), but also reduces forskolin-induced cAMP production
(sensitive to pertussis toxin, thus indicating Gi protein coupling)
(6). The ß-alanine-induced receptor activation also increased
intracellular calcium concentration and stimulated ERK1/2
phosphorylation in Human embryonic kidney 293 (HEK293)
cells (9). In cells with coexpression of MrgD and MrgE, ß-
alanine-induced ERK1/2 phosphorylation was increased, while
MrgD internalization was reduced followed by a prolonged
calcium influx (9). Coexpression of MrgD and voltage-sensitive
KCNQ2/3 potassium channels in HEK293 cells resulted in a
strong inhibition of KCNQ2/3 currents (neuronal “M current”)
upon ß-alanine-induced receptor activation. This effect was
blocked completely by phospholipase C (PLC) inhibition (again
indicating Gq protein coupling) and partially by pertussis toxin
(indicating Gi protein coupling). Interestingly, results were
partially confirmed when experiments have been performed in
isolated DRG neurons. Here, KCNQ2/3 current activation was
partially inhibited by PLC blockade and blocked completely by
pertussis toxin (15).
While opening of KCNQ channels hyperpolarizes the cell
membrane, opening calcium-activated chloride channels leads
to a depolarization. KCNQ channels can be inhibited by PIP2
depletion, thus by activation of Gq protein-coupled receptors. An
increase in intracellular calcium, also resulting from Gq protein
activation, opens calcium-activated chloride channels. Thus, it
was not very surprising that in MrgD-expressing oocytes, a ß-
alanine-induced current was found to be sensitive to calcium-
activated chloride channel inhibitors and calcium chelators.
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TABLE 1 | Overview of MrgD receptor G protein-coupling under different conditions.
G protein Effect Expression system or tissue Ligand References
Gq Ca








+ MrgD, MrgE coexpression
ß-alanine (9)
Gq Inhibition of KCNQ2/3 current CHO cells
+ MrgD, KCNQ2/3 coexpression
ß-alanine (15)
Gq Partial inhibition of KCNQ2/3 current Isolated DRG neurons ß-alanine (15)
Gq Opening of CACC channels oocytes
+ MrgD expression
ß-alanine (16)
Gq Decreased secretion, expression, and blood
level of leptin
Perirenal adipose tissue alamandine (17)
Gs Increased cAMP level HEK293 cells
+ MrgD expression
Ang (1-7) (18)
Gs Increased cAMP level Mesangial cells Ang (1–7) (18)
Gs
(Gi)
Increased cAMP level Primary mesangial and endothelial cells Alamandine
(higher doses)
(19)
Gi Decreased cAMP level CHO cells
+ MrgD expression
ß-alanine (6)
Gi Partial inhibition of KCNQ2/3 current CHO cells
+ MrgD,KCNQ2/3 coexpression
ß-alanine (15)
Gi Inhibition of KCNQ2/3 current Isolated DRG neurons ß-alanine (15)
Gi Reversal of hyperhomocysteinamia-induced
vascular dysfunction
Isolated abdominal aorta of New Zealand
White rabbits
alamandine (20)
Gi Increase in blood pressure and sympathetic
outflow
Microinjection in paraventricular nucleus of
WKY and SHR rats
alamandine (21)
The chloride current was reduced by phospholipase C (PLC)
inhibition and by inositol 1,4,5-trisphosphate (IP3) receptor
antisense nucleotides, while phosphokinase C (PKC) inhibition
had no effect (16). This indicates a signal transduction from
MrgD to CaCC via calcium as second messenger, while the
transduction pathway diacylglycerol (DAG)/PKC is neglectable
under those conditions.
Thus, ß-alanine is able to signal via MrgD receptor activation
inducing Gq or Gi protein-coupled pathways. It remains unclear,
which transduction is used under physiological conditions,
though both pathways are involved in the regulation of neuronal
excitability. This suggests a limitation of ß-alanine as a ligand of
MrgD receptors expressed in neurons.
Other ligands of the MrgD receptor are more relevant
in the cardiovascular context. Ang (1-7), known as a ligand
for the Mas receptor, is also binding to the MrgD receptor
and stimulating the Gs protein-coupled signaling pathway.
Moreover, it increased cyclic adenosine monophosphate (cAMP)
concentrations in MrgD-transfected HEK293 cells and in
mesangial cells, but not in MrgD-deficient mesangial cells (18).
Similar effects were found for alamandine, an endogenous
MrgD ligand circulating in the human blood. It elevated cAMP
concentration in primary endothelial and mesangial cells (18),
also suggesting Gs coupling. Interestingly, higher concentrations
of alamandine were also involved in the Gi-coupled pathway
in primary mesangial and endothelial cells, showing specific
pharmacodynamics properties of alamandine compared to Ang
(1-7) (19). Reversal of hyperhomocysteinamia-induced vascular
dysfunction by alamandine in isolated abdominal aorta of New
Zealand White rabbits was dependent on Gi protein signaling
(20). In blood vessels of New Zealand White rabbits on an
atherogenic diet and control animals, alamandine enhanced
acetylcholine-mediated vasodilation in thoracic aorta, and iliac
artery, while vasodilation of renal arteries by acetylcholine was
reduced. In total, the vasoreactivity of alamandine was reduced
in atherogenic arteries compared to controls (12). In vivo,
participation of the Gi signaling pathway in an alamandine
effect could be shown after microinjection of alamandine in the
paraventricular nucleus of normotensive Wistar Kyoto (WKY)
rats and SHR rats. Blood pressure as well as sympathetic outflow
increased in both groups upon activation of MrgD receptor
dependent on cAMP and protein kinase A (PKA), while the
increase in SHR rats was larger than in the control group (21).
Alamandine decreases secretion, expression, and blood levels
of leptin. When leptin levels are low, expenditure is reduced
and hunger is increased (22). Genetic deficiency of leptin or
its receptor, in both mice and humans, “fools” the brain into
thinking that fat stores are absent, resulting in extreme hunger
and obesity (22). However, the role of leptin in maintaining
energy balance is asymmetric; low levels strongly promote
restoration of fat stores, whereas high levels weakly resist obesity.
Another feedback signal probably serves this latter function (i.e.,
to resist obesity), but the identity of the signal (or signals) is
unknown (22). Remarkably, leptin plasma levels are elevated
under hypertensive conditions (23). This suggests a potentially
protective role of the protein. This effect in perirenal adipose
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tissue of Wistar rats was mediated by Gq protein signaling
and also involved c-Src, p38 mitogen-activated protein, and IκB
activation (17). Additionally, alamandine induced expression of
iNOS and plasminogen activator inhibitor-1 (PAI-1) in adipose
tissue and isolated adipocytes (17).
ALAMANDINE AND VASODILATION
Reduction in leptin expression by alamandine was reversed by
the NOS inhibitor L-NG-nitroarginine methyl ester (L-NAME),
while leptin expression was inhibited by S-nitroso-L-glutathione,
an donor of nitric oxide (NO) (17). The vasodilating molecule
NO is produced by the enzymes iNOS, eNOS, and nNOS. Indeed,
observed vasoreactive effects of alamandine are mediated by
NO release. Leao et al. compared the vasorelaxing effects of
alamandine in spontaneously hypertensive stroke prone (SHRSP)
rats. They found an enhanced vasorelaxation in SHRSP rats
mediated by release of NO and prostaglandins1. At least in
aortic rings, the vasodilating effects of alamandine are sensitive
to inhibition of endothelial NO release by L-NAME. Also, they
can be blocked by ß-alanine, probably through competitive
inhibition (24).
The literature about vasodilating effects of alamandine
mediated through MrgD receptor activation is very rare; some
studies are available only as abstracts. Local vasodilation,
particularly in arterial beds with high peripheral resistance,
could be a powerful tool in fighting hypertension. Thus, further
studies are needed to investigate the involvement of the MrgD
receptor and its ligand alamandine. Both molecules, i.e., MrgD
and alamandine, could be of interest for the development of new
therapies against cardiovascular diseases. The fact that the new
RAS hormone alamandine can be easily administered orally as
a HPβCD inclusion compound and produced antihypertensive
effects in spontaneously hypertensive rats and pronounced
protective effects in cardiac fibrosis, opens new perspectives
for exploring the therapeutic potential of angiotensin-(1–7)–
related peptides. The identification of 2 novel components
of the RAS, alamandine and its receptor, will be important
for improving our understanding of the physiological and
pathophysiological role of the this key regulatory system. It
is possible that these 2 novel compounds of the RAS play
a pathophysiological role in kidney failure since hemodialysis
patients seem to exhibit increased serum concentrations of
alamandine (as measured by alamandine /Ang II ratios in 5
patients) (24).
MRGD RECEPTORS, ALAMANDINE, AND
CARDIOVASCULAR FUNCTION
Several studies have been published showing an effect of
alamandine-induced MrgD activation on blood pressure. In
renovascular hypertensive rats, alamandine showed a biphasic
hemodynamic effect after infusion: AT1R-mediated signaling
by alamandine under normal conditions (normotensive rats) is
1https://www.ahajournals.org/doi/10.1161/hyp.68.suppl_1.p281
superimposed by activation of a PD123319-sensitive receptor
under pathophysiological conditions (renovascular hypertensive
2K1C rats) (25). PD123319 has been regarded as an specific
AT2R inhibitor, but also inhibits MrgD receptors, as found
in experiments using knock-out animals (26). This study is
the only one hypothesizing so far that alamandine is also
signaling via AT1R activation. The authors suggest an agonistic
effect of alamandine based on the knowledge of the structural
related Ang (1-7) being an AT1R agonist (27). When injected
into the caudal ventrolateral medulla, alamandine showed an
MrgD-dependent hypotensive effect in normotensive control
rats, while the blood pressure curve was U-shaped in 2K1C
animals (28). In vivo, oral doses of alamandine lead to a
long-lasting antihypertensive effect in SHR rats, as well as to
an anti-fibrotic affect in rats treated with isoprotenerol (24).
Effects specifically in the heart were seen upon treatment
of cultured neonatal rat cardiomyocytes with alamandine.
The treatment prevented angiotensin II-induced hypertrophy
via MrgD activation involving a 5′ AMP-activated protein
kinase (AMPK)/NO pathway (29). In the same cell type, and
additionally in mice treated with lipopolysaccharide (LPS),
alamandine attenuated sepsis-induced cardiac dysfunction via
inhibition of mitogen-activated protein kinase (MAPK) signaling
pathways. Alamandine prevented myocardial inflammation,
apopotosis, and autophagy induced by lipopolysaccharides (LPS).
It also reversed decreases in cardiac ejection fraction and
NOS expression, leading to reduced blood pressure (30). As
previously mentioned, administration of alamandine attenuated
hypertension and alleviated cardiac hypertrophy in angiotensin
II-treated SHR hearts (14). In normotensive SD rats, alamandine
administration in vivo increased the plasma level of atrial
natriuretic peptide (ANP) via MrgD activation. It was also
improving postischemic left ventricular pressure and decreasing
the infarct size, while decreasing apoptotic protein and increasing
antioxidative protein expression (31).
SUMMARY
There are only a few studies about the MrgD receptor and
its endogenous ligand alamandine, but many of them show a
clear relevance of both molecules for the cardiovascular system.
Though the molecular details of the signaling pathways are not
completely evolved yet, some physiological effects of receptor and
ligand are proven.
Most striking is an increased expression of NOS enzymes
upon alamandine-induced activation of MrgD, leading to
NO-mediated vasodilation. The induced vasodilation is
sufficient for a reversal of vascular endothelial dysfunction
as well as an alleviation of the venous return to the heart,
thus decreasing the preload of the heart. The vasodilation
is subsidized by an alamandine-induced increase in ANP
plasma levels. The depressor effect of MrgD activation is
masking a preceding pressure effect in healthy animals,
while the mechanism seems dysfunctional in rat models of
hypertension. Also relevant is an anti-fibrotic effect, preventing
hypertrophy of cardiomyocytes. The protective impact of
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alamandine-induced MrgD activation is strengthened by
changes in expression of proteins improving the outcome of
cardiac infarcts.
Though studies investigating alamandine and/or MrgD
receptor are done in different models, the findings are
consistent and fit into a bigger picture. All alamandine-induced
MrgD receptor actions are affecting the cardiovascular
system, so targeting both molecules can be a worthwhile
goal for the development of future antihypertensive and
cardioprotective drugs.
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